Oseltamivir: A New Option for the Management of Influenza in Children

Marcia L. Buck, Pharm.D., FCCP

Pediatr Pharm. 2001;7(2) 

In This Article


Oseltamivir, one of the new neuraminidase inhibitors, appears to be a safe and effective therapy for the prevention and treatment of influenza. The primary disadvantages to its use are the need to initiate treatment within 2 days of the onset of symptoms and cost. The recent FDA approval of this agent for use in children and the availability of an oral liquid dosage formulation will likely result in a significant change in the management of influenza in the pediatric population.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.